Perspectives	O
on	O
cardiovascular	B:C0007226
effects	O
of	O
incretin	O
-	O
based	O
drugs	O
:	O
From	O
bedside	O
to	O
bench	O
,	O
return	O
trip	O
.	O

Perspectives	O
on	O
cardiovascular	O
effects	O
of	O
incretin	B:C1562292
-	O
based	O
drugs	O
:	O
From	O
bedside	O
to	O
bench	O
,	O
return	O
trip	O
.	O

Perspectives	O
on	O
cardiovascular	O
effects	O
of	O
incretin	O
-	O
based	O
drugs	B:C1254351
:	O
From	O
bedside	O
to	O
bench	O
,	O
return	O
trip	O
.	O

Recently	O
,	O
cardiovascular	B:C0007226
outcome	O
trials	O
with	O
glucose	O
-	O
lowering	O
drugs	O
used	O
in	O
type	O
2	I:C0011860
diabetes	I:C0011860
mellitus	I:C0011860
,	O
namely	O
glucagon	O
-	I:C0378073
like	I:C0378073
peptide	I:C0378073
-	I:C0378073
1	I:C0378073
receptor	I:C0378073
agonists	O
(	O
glucagon	O
-	I:C0243192
like	I:C0243192
peptide	I:C0243192
-	I:C0243192
1	I:C0243192
receptor	I:C0243192
agonists	I:C0243192
)	O
,	O
liraglutide	O
and	O
semaglutide	O
,	O
showed	O
a	O
reduction	O
in	O
cardiovascular	O
events	I:C1320716
,	O
which	O
had	O
not	O
been	O
observed	O
in	O
trials	O
with	O
other	O
incretin	O
-	O
based	O
drugs	O
,	O
such	O
as	O
lixisenatide	O
or	O
with	O
dipeptidyl	O
peptidase	I:C1827106
-	I:C1827106
4	I:C1827106
inhibitors	I:C1827106
(	O
dipeptidyl	O
peptidase	I:C1827106
-	I:C1827106
4	I:C1827106
inhibitors	I:C1827106
)	O
.	O

Recently	O
,	O
cardiovascular	O
outcome	O
trials	B:C0008976
with	O
glucose	O
-	O
lowering	O
drugs	O
used	O
in	O
type	O
2	I:C0011860
diabetes	I:C0011860
mellitus	I:C0011860
,	O
namely	O
glucagon	O
-	I:C0378073
like	I:C0378073
peptide	I:C0378073
-	I:C0378073
1	I:C0378073
receptor	I:C0378073
agonists	O
(	O
glucagon	O
-	I:C0243192
like	I:C0243192
peptide	I:C0243192
-	I:C0243192
1	I:C0243192
receptor	I:C0243192
agonists	I:C0243192
)	O
,	O
liraglutide	O
and	O
semaglutide	O
,	O
showed	O
a	O
reduction	O
in	O
cardiovascular	O
events	I:C1320716
,	O
which	O
had	O
not	O
been	O
observed	O
in	O
trials	O
with	O
other	O
incretin	O
-	O
based	O
drugs	O
,	O
such	O
as	O
lixisenatide	O
or	O
with	O
dipeptidyl	O
peptidase	I:C1827106
-	I:C1827106
4	I:C1827106
inhibitors	I:C1827106
(	O
dipeptidyl	O
peptidase	I:C1827106
-	I:C1827106
4	I:C1827106
inhibitors	I:C1827106
)	O
.	O

Recently	O
,	O
cardiovascular	O
outcome	O
trials	O
with	O
glucose	B:C0017725
-	O
lowering	O
drugs	O
used	O
in	O
type	O
2	I:C0011860
diabetes	I:C0011860
mellitus	I:C0011860
,	O
namely	O
glucagon	O
-	I:C0378073
like	I:C0378073
peptide	I:C0378073
-	I:C0378073
1	I:C0378073
receptor	I:C0378073
agonists	O
(	O
glucagon	O
-	I:C0243192
like	I:C0243192
peptide	I:C0243192
-	I:C0243192
1	I:C0243192
receptor	I:C0243192
agonists	I:C0243192
)	O
,	O
liraglutide	O
and	O
semaglutide	O
,	O
showed	O
a	O
reduction	O
in	O
cardiovascular	O
events	I:C1320716
,	O
which	O
had	O
not	O
been	O
observed	O
in	O
trials	O
with	O
other	O
incretin	O
-	O
based	O
drugs	O
,	O
such	O
as	O
lixisenatide	O
or	O
with	O
dipeptidyl	O
peptidase	I:C1827106
-	I:C1827106
4	I:C1827106
inhibitors	I:C1827106
(	O
dipeptidyl	O
peptidase	I:C1827106
-	I:C1827106
4	I:C1827106
inhibitors	I:C1827106
)	O
.	O

Recently	O
,	O
cardiovascular	O
outcome	O
trials	O
with	O
glucose	O
-	O
lowering	O
drugs	B:C1254351
used	O
in	O
type	O
2	I:C0011860
diabetes	I:C0011860
mellitus	I:C0011860
,	O
namely	O
glucagon	O
-	I:C0378073
like	I:C0378073
peptide	I:C0378073
-	I:C0378073
1	I:C0378073
receptor	I:C0378073
agonists	O
(	O
glucagon	O
-	I:C0243192
like	I:C0243192
peptide	I:C0243192
-	I:C0243192
1	I:C0243192
receptor	I:C0243192
agonists	I:C0243192
)	O
,	O
liraglutide	O
and	O
semaglutide	O
,	O
showed	O
a	O
reduction	O
in	O
cardiovascular	O
events	I:C1320716
,	O
which	O
had	O
not	O
been	O
observed	O
in	O
trials	O
with	O
other	O
incretin	O
-	O
based	O
drugs	O
,	O
such	O
as	O
lixisenatide	O
or	O
with	O
dipeptidyl	O
peptidase	I:C1827106
-	I:C1827106
4	I:C1827106
inhibitors	I:C1827106
(	O
dipeptidyl	O
peptidase	I:C1827106
-	I:C1827106
4	I:C1827106
inhibitors	I:C1827106
)	O
.	O

Recently	O
,	O
cardiovascular	O
outcome	O
trials	O
with	O
glucose	O
-	O
lowering	O
drugs	O
used	O
in	O
type	B:C0011860
2	I:C0011860
diabetes	I:C0011860
mellitus	I:C0011860
,	O
namely	O
glucagon	O
-	I:C0378073
like	I:C0378073
peptide	I:C0378073
-	I:C0378073
1	I:C0378073
receptor	I:C0378073
agonists	O
(	O
glucagon	O
-	I:C0243192
like	I:C0243192
peptide	I:C0243192
-	I:C0243192
1	I:C0243192
receptor	I:C0243192
agonists	I:C0243192
)	O
,	O
liraglutide	O
and	O
semaglutide	O
,	O
showed	O
a	O
reduction	O
in	O
cardiovascular	O
events	I:C1320716
,	O
which	O
had	O
not	O
been	O
observed	O
in	O
trials	O
with	O
other	O
incretin	O
-	O
based	O
drugs	O
,	O
such	O
as	O
lixisenatide	O
or	O
with	O
dipeptidyl	O
peptidase	I:C1827106
-	I:C1827106
4	I:C1827106
inhibitors	I:C1827106
(	O
dipeptidyl	O
peptidase	I:C1827106
-	I:C1827106
4	I:C1827106
inhibitors	I:C1827106
)	O
.	O

Recently	O
,	O
cardiovascular	O
outcome	O
trials	O
with	O
glucose	O
-	O
lowering	O
drugs	O
used	O
in	O
type	O
2	I:C0011860
diabetes	I:C0011860
mellitus	I:C0011860
,	O
namely	O
glucagon	B:C0378073
-	I:C0378073
like	I:C0378073
peptide	I:C0378073
-	I:C0378073
1	I:C0378073
receptor	I:C0378073
agonists	O
(	O
glucagon	O
-	I:C0243192
like	I:C0243192
peptide	I:C0243192
-	I:C0243192
1	I:C0243192
receptor	I:C0243192
agonists	I:C0243192
)	O
,	O
liraglutide	O
and	O
semaglutide	O
,	O
showed	O
a	O
reduction	O
in	O
cardiovascular	O
events	I:C1320716
,	O
which	O
had	O
not	O
been	O
observed	O
in	O
trials	O
with	O
other	O
incretin	O
-	O
based	O
drugs	O
,	O
such	O
as	O
lixisenatide	O
or	O
with	O
dipeptidyl	O
peptidase	I:C1827106
-	I:C1827106
4	I:C1827106
inhibitors	I:C1827106
(	O
dipeptidyl	O
peptidase	I:C1827106
-	I:C1827106
4	I:C1827106
inhibitors	I:C1827106
)	O
.	O

Recently	O
,	O
cardiovascular	O
outcome	O
trials	O
with	O
glucose	O
-	O
lowering	O
drugs	O
used	O
in	O
type	O
2	I:C0011860
diabetes	I:C0011860
mellitus	I:C0011860
,	O
namely	O
glucagon	O
-	I:C0378073
like	I:C0378073
peptide	I:C0378073
-	I:C0378073
1	I:C0378073
receptor	I:C0378073
agonists	B:C0243192
(	O
glucagon	O
-	I:C0243192
like	I:C0243192
peptide	I:C0243192
-	I:C0243192
1	I:C0243192
receptor	I:C0243192
agonists	I:C0243192
)	O
,	O
liraglutide	O
and	O
semaglutide	O
,	O
showed	O
a	O
reduction	O
in	O
cardiovascular	O
events	I:C1320716
,	O
which	O
had	O
not	O
been	O
observed	O
in	O
trials	O
with	O
other	O
incretin	O
-	O
based	O
drugs	O
,	O
such	O
as	O
lixisenatide	O
or	O
with	O
dipeptidyl	O
peptidase	I:C1827106
-	I:C1827106
4	I:C1827106
inhibitors	I:C1827106
(	O
dipeptidyl	O
peptidase	I:C1827106
-	I:C1827106
4	I:C1827106
inhibitors	I:C1827106
)	O
.	O

Recently	O
,	O
cardiovascular	O
outcome	O
trials	O
with	O
glucose	O
-	O
lowering	O
drugs	O
used	O
in	O
type	O
2	I:C0011860
diabetes	I:C0011860
mellitus	I:C0011860
,	O
namely	O
glucagon	O
-	I:C0378073
like	I:C0378073
peptide	I:C0378073
-	I:C0378073
1	I:C0378073
receptor	I:C0378073
agonists	O
(	O
glucagon	B:C0243192
-	I:C0243192
like	I:C0243192
peptide	I:C0243192
-	I:C0243192
1	I:C0243192
receptor	I:C0243192
agonists	I:C0243192
)	O
,	O
liraglutide	O
and	O
semaglutide	O
,	O
showed	O
a	O
reduction	O
in	O
cardiovascular	O
events	I:C1320716
,	O
which	O
had	O
not	O
been	O
observed	O
in	O
trials	O
with	O
other	O
incretin	O
-	O
based	O
drugs	O
,	O
such	O
as	O
lixisenatide	O
or	O
with	O
dipeptidyl	O
peptidase	I:C1827106
-	I:C1827106
4	I:C1827106
inhibitors	I:C1827106
(	O
dipeptidyl	O
peptidase	I:C1827106
-	I:C1827106
4	I:C1827106
inhibitors	I:C1827106
)	O
.	O

Recently	O
,	O
cardiovascular	O
outcome	O
trials	O
with	O
glucose	O
-	O
lowering	O
drugs	O
used	O
in	O
type	O
2	I:C0011860
diabetes	I:C0011860
mellitus	I:C0011860
,	O
namely	O
glucagon	O
-	I:C0378073
like	I:C0378073
peptide	I:C0378073
-	I:C0378073
1	I:C0378073
receptor	I:C0378073
agonists	O
(	O
glucagon	O
-	I:C0243192
like	I:C0243192
peptide	I:C0243192
-	I:C0243192
1	I:C0243192
receptor	I:C0243192
agonists	I:C0243192
)	O
,	O
liraglutide	B:C1456408
and	O
semaglutide	O
,	O
showed	O
a	O
reduction	O
in	O
cardiovascular	O
events	I:C1320716
,	O
which	O
had	O
not	O
been	O
observed	O
in	O
trials	O
with	O
other	O
incretin	O
-	O
based	O
drugs	O
,	O
such	O
as	O
lixisenatide	O
or	O
with	O
dipeptidyl	O
peptidase	I:C1827106
-	I:C1827106
4	I:C1827106
inhibitors	I:C1827106
(	O
dipeptidyl	O
peptidase	I:C1827106
-	I:C1827106
4	I:C1827106
inhibitors	I:C1827106
)	O
.	O

Recently	O
,	O
cardiovascular	O
outcome	O
trials	O
with	O
glucose	O
-	O
lowering	O
drugs	O
used	O
in	O
type	O
2	I:C0011860
diabetes	I:C0011860
mellitus	I:C0011860
,	O
namely	O
glucagon	O
-	I:C0378073
like	I:C0378073
peptide	I:C0378073
-	I:C0378073
1	I:C0378073
receptor	I:C0378073
agonists	O
(	O
glucagon	O
-	I:C0243192
like	I:C0243192
peptide	I:C0243192
-	I:C0243192
1	I:C0243192
receptor	I:C0243192
agonists	I:C0243192
)	O
,	O
liraglutide	O
and	O
semaglutide	B:C3885068
,	O
showed	O
a	O
reduction	O
in	O
cardiovascular	O
events	I:C1320716
,	O
which	O
had	O
not	O
been	O
observed	O
in	O
trials	O
with	O
other	O
incretin	O
-	O
based	O
drugs	O
,	O
such	O
as	O
lixisenatide	O
or	O
with	O
dipeptidyl	O
peptidase	I:C1827106
-	I:C1827106
4	I:C1827106
inhibitors	I:C1827106
(	O
dipeptidyl	O
peptidase	I:C1827106
-	I:C1827106
4	I:C1827106
inhibitors	I:C1827106
)	O
.	O

Recently	O
,	O
cardiovascular	O
outcome	O
trials	O
with	O
glucose	O
-	O
lowering	O
drugs	O
used	O
in	O
type	O
2	I:C0011860
diabetes	I:C0011860
mellitus	I:C0011860
,	O
namely	O
glucagon	O
-	I:C0378073
like	I:C0378073
peptide	I:C0378073
-	I:C0378073
1	I:C0378073
receptor	I:C0378073
agonists	O
(	O
glucagon	O
-	I:C0243192
like	I:C0243192
peptide	I:C0243192
-	I:C0243192
1	I:C0243192
receptor	I:C0243192
agonists	I:C0243192
)	O
,	O
liraglutide	O
and	O
semaglutide	O
,	O
showed	O
a	O
reduction	O
in	O
cardiovascular	B:C1320716
events	I:C1320716
,	O
which	O
had	O
not	O
been	O
observed	O
in	O
trials	O
with	O
other	O
incretin	O
-	O
based	O
drugs	O
,	O
such	O
as	O
lixisenatide	O
or	O
with	O
dipeptidyl	O
peptidase	I:C1827106
-	I:C1827106
4	I:C1827106
inhibitors	I:C1827106
(	O
dipeptidyl	O
peptidase	I:C1827106
-	I:C1827106
4	I:C1827106
inhibitors	I:C1827106
)	O
.	O

Recently	O
,	O
cardiovascular	O
outcome	O
trials	O
with	O
glucose	O
-	O
lowering	O
drugs	O
used	O
in	O
type	O
2	I:C0011860
diabetes	I:C0011860
mellitus	I:C0011860
,	O
namely	O
glucagon	O
-	I:C0378073
like	I:C0378073
peptide	I:C0378073
-	I:C0378073
1	I:C0378073
receptor	I:C0378073
agonists	O
(	O
glucagon	O
-	I:C0243192
like	I:C0243192
peptide	I:C0243192
-	I:C0243192
1	I:C0243192
receptor	I:C0243192
agonists	I:C0243192
)	O
,	O
liraglutide	O
and	O
semaglutide	O
,	O
showed	O
a	O
reduction	O
in	O
cardiovascular	O
events	I:C1320716
,	O
which	O
had	O
not	O
been	O
observed	O
in	O
trials	B:C0008976
with	O
other	O
incretin	O
-	O
based	O
drugs	O
,	O
such	O
as	O
lixisenatide	O
or	O
with	O
dipeptidyl	O
peptidase	I:C1827106
-	I:C1827106
4	I:C1827106
inhibitors	I:C1827106
(	O
dipeptidyl	O
peptidase	I:C1827106
-	I:C1827106
4	I:C1827106
inhibitors	I:C1827106
)	O
.	O

Recently	O
,	O
cardiovascular	O
outcome	O
trials	O
with	O
glucose	O
-	O
lowering	O
drugs	O
used	O
in	O
type	O
2	I:C0011860
diabetes	I:C0011860
mellitus	I:C0011860
,	O
namely	O
glucagon	O
-	I:C0378073
like	I:C0378073
peptide	I:C0378073
-	I:C0378073
1	I:C0378073
receptor	I:C0378073
agonists	O
(	O
glucagon	O
-	I:C0243192
like	I:C0243192
peptide	I:C0243192
-	I:C0243192
1	I:C0243192
receptor	I:C0243192
agonists	I:C0243192
)	O
,	O
liraglutide	O
and	O
semaglutide	O
,	O
showed	O
a	O
reduction	O
in	O
cardiovascular	O
events	I:C1320716
,	O
which	O
had	O
not	O
been	O
observed	O
in	O
trials	O
with	O
other	O
incretin	B:C1562292
-	O
based	O
drugs	O
,	O
such	O
as	O
lixisenatide	O
or	O
with	O
dipeptidyl	O
peptidase	I:C1827106
-	I:C1827106
4	I:C1827106
inhibitors	I:C1827106
(	O
dipeptidyl	O
peptidase	I:C1827106
-	I:C1827106
4	I:C1827106
inhibitors	I:C1827106
)	O
.	O

Recently	O
,	O
cardiovascular	O
outcome	O
trials	O
with	O
glucose	O
-	O
lowering	O
drugs	O
used	O
in	O
type	O
2	I:C0011860
diabetes	I:C0011860
mellitus	I:C0011860
,	O
namely	O
glucagon	O
-	I:C0378073
like	I:C0378073
peptide	I:C0378073
-	I:C0378073
1	I:C0378073
receptor	I:C0378073
agonists	O
(	O
glucagon	O
-	I:C0243192
like	I:C0243192
peptide	I:C0243192
-	I:C0243192
1	I:C0243192
receptor	I:C0243192
agonists	I:C0243192
)	O
,	O
liraglutide	O
and	O
semaglutide	O
,	O
showed	O
a	O
reduction	O
in	O
cardiovascular	O
events	I:C1320716
,	O
which	O
had	O
not	O
been	O
observed	O
in	O
trials	O
with	O
other	O
incretin	O
-	O
based	O
drugs	B:C1254351
,	O
such	O
as	O
lixisenatide	O
or	O
with	O
dipeptidyl	O
peptidase	I:C1827106
-	I:C1827106
4	I:C1827106
inhibitors	I:C1827106
(	O
dipeptidyl	O
peptidase	I:C1827106
-	I:C1827106
4	I:C1827106
inhibitors	I:C1827106
)	O
.	O

Recently	O
,	O
cardiovascular	O
outcome	O
trials	O
with	O
glucose	O
-	O
lowering	O
drugs	O
used	O
in	O
type	O
2	I:C0011860
diabetes	I:C0011860
mellitus	I:C0011860
,	O
namely	O
glucagon	O
-	I:C0378073
like	I:C0378073
peptide	I:C0378073
-	I:C0378073
1	I:C0378073
receptor	I:C0378073
agonists	O
(	O
glucagon	O
-	I:C0243192
like	I:C0243192
peptide	I:C0243192
-	I:C0243192
1	I:C0243192
receptor	I:C0243192
agonists	I:C0243192
)	O
,	O
liraglutide	O
and	O
semaglutide	O
,	O
showed	O
a	O
reduction	O
in	O
cardiovascular	O
events	I:C1320716
,	O
which	O
had	O
not	O
been	O
observed	O
in	O
trials	O
with	O
other	O
incretin	O
-	O
based	O
drugs	O
,	O
such	O
as	O
lixisenatide	B:C2973895
or	O
with	O
dipeptidyl	O
peptidase	I:C1827106
-	I:C1827106
4	I:C1827106
inhibitors	I:C1827106
(	O
dipeptidyl	O
peptidase	I:C1827106
-	I:C1827106
4	I:C1827106
inhibitors	I:C1827106
)	O
.	O

Recently	O
,	O
cardiovascular	O
outcome	O
trials	O
with	O
glucose	O
-	O
lowering	O
drugs	O
used	O
in	O
type	O
2	I:C0011860
diabetes	I:C0011860
mellitus	I:C0011860
,	O
namely	O
glucagon	O
-	I:C0378073
like	I:C0378073
peptide	I:C0378073
-	I:C0378073
1	I:C0378073
receptor	I:C0378073
agonists	O
(	O
glucagon	O
-	I:C0243192
like	I:C0243192
peptide	I:C0243192
-	I:C0243192
1	I:C0243192
receptor	I:C0243192
agonists	I:C0243192
)	O
,	O
liraglutide	O
and	O
semaglutide	O
,	O
showed	O
a	O
reduction	O
in	O
cardiovascular	O
events	I:C1320716
,	O
which	O
had	O
not	O
been	O
observed	O
in	O
trials	O
with	O
other	O
incretin	O
-	O
based	O
drugs	O
,	O
such	O
as	O
lixisenatide	O
or	O
with	O
dipeptidyl	B:C1827106
peptidase	I:C1827106
-	I:C1827106
4	I:C1827106
inhibitors	I:C1827106
(	O
dipeptidyl	O
peptidase	I:C1827106
-	I:C1827106
4	I:C1827106
inhibitors	I:C1827106
)	O
.	O

Recently	O
,	O
cardiovascular	O
outcome	O
trials	O
with	O
glucose	O
-	O
lowering	O
drugs	O
used	O
in	O
type	O
2	I:C0011860
diabetes	I:C0011860
mellitus	I:C0011860
,	O
namely	O
glucagon	O
-	I:C0378073
like	I:C0378073
peptide	I:C0378073
-	I:C0378073
1	I:C0378073
receptor	I:C0378073
agonists	O
(	O
glucagon	O
-	I:C0243192
like	I:C0243192
peptide	I:C0243192
-	I:C0243192
1	I:C0243192
receptor	I:C0243192
agonists	I:C0243192
)	O
,	O
liraglutide	O
and	O
semaglutide	O
,	O
showed	O
a	O
reduction	O
in	O
cardiovascular	O
events	I:C1320716
,	O
which	O
had	O
not	O
been	O
observed	O
in	O
trials	O
with	O
other	O
incretin	O
-	O
based	O
drugs	O
,	O
such	O
as	O
lixisenatide	O
or	O
with	O
dipeptidyl	O
peptidase	I:C1827106
-	I:C1827106
4	I:C1827106
inhibitors	I:C1827106
(	O
dipeptidyl	B:C1827106
peptidase	I:C1827106
-	I:C1827106
4	I:C1827106
inhibitors	I:C1827106
)	O
.	O

Mechanisms	O
underlying	O
the	O
observed	O
cardiovascular	B:C0007226
differences	O
between	O
dipeptidyl	O
peptidase	I:C1827106
-	I:C1827106
4	I:C1827106
inhibitors	I:C1827106
and	O
GLP1	O
-	I:C0243192
RA	I:C0243192
,	O
and	O
across	O
individual	O
GLP1	O
-	I:C0243192
RA	I:C0243192
are	O
poorly	O
understood	O
.	O

Mechanisms	O
underlying	O
the	O
observed	O
cardiovascular	O
differences	O
between	O
dipeptidyl	B:C1827106
peptidase	I:C1827106
-	I:C1827106
4	I:C1827106
inhibitors	I:C1827106
and	O
GLP1	O
-	I:C0243192
RA	I:C0243192
,	O
and	O
across	O
individual	O
GLP1	O
-	I:C0243192
RA	I:C0243192
are	O
poorly	O
understood	O
.	O

Mechanisms	O
underlying	O
the	O
observed	O
cardiovascular	O
differences	O
between	O
dipeptidyl	O
peptidase	I:C1827106
-	I:C1827106
4	I:C1827106
inhibitors	I:C1827106
and	O
GLP1	B:C0243192
-	I:C0243192
RA	I:C0243192
,	O
and	O
across	O
individual	O
GLP1	O
-	I:C0243192
RA	I:C0243192
are	O
poorly	O
understood	O
.	O

Mechanisms	O
underlying	O
the	O
observed	O
cardiovascular	O
differences	O
between	O
dipeptidyl	O
peptidase	I:C1827106
-	I:C1827106
4	I:C1827106
inhibitors	I:C1827106
and	O
GLP1	O
-	I:C0243192
RA	I:C0243192
,	O
and	O
across	O
individual	O
GLP1	B:C0243192
-	I:C0243192
RA	I:C0243192
are	O
poorly	O
understood	O
.	O

This	O
review	B:C0282443
is	O
aimed	O
at	O
collecting	O
and	O
summarizing	O
available	O
evidence	O
from	O
experimental	O
and	O
mechanistic	O
studies	I:C0681814
on	O
the	O
action	O
of	O
GLP1	O
-	I:C0243192
RA	I:C0243192
and	O
dipeptidyl	O
peptidase	I:C1827106
-	I:C1827106
4	I:C1827106
inhibitors	I:C1827106
on	O
the	O
cardiovascular	O
system	I:C0007226
,	O
both	O
deriving	O
from	O
clinical	O
and	O
pre-clinical	O
sources	O
.	O

This	O
review	O
is	O
aimed	O
at	O
collecting	O
and	O
summarizing	O
available	O
evidence	O
from	O
experimental	B:C0681814
and	O
mechanistic	O
studies	I:C0681814
on	O
the	O
action	O
of	O
GLP1	O
-	I:C0243192
RA	I:C0243192
and	O
dipeptidyl	O
peptidase	I:C1827106
-	I:C1827106
4	I:C1827106
inhibitors	I:C1827106
on	O
the	O
cardiovascular	O
system	I:C0007226
,	O
both	O
deriving	O
from	O
clinical	O
and	O
pre-clinical	O
sources	O
.	O

This	O
review	O
is	O
aimed	O
at	O
collecting	O
and	O
summarizing	O
available	O
evidence	O
from	O
experimental	O
and	O
mechanistic	B:C0681814
studies	I:C0681814
on	O
the	O
action	O
of	O
GLP1	O
-	I:C0243192
RA	I:C0243192
and	O
dipeptidyl	O
peptidase	I:C1827106
-	I:C1827106
4	I:C1827106
inhibitors	I:C1827106
on	O
the	O
cardiovascular	O
system	I:C0007226
,	O
both	O
deriving	O
from	O
clinical	O
and	O
pre-clinical	O
sources	O
.	O

This	O
review	O
is	O
aimed	O
at	O
collecting	O
and	O
summarizing	O
available	O
evidence	O
from	O
experimental	O
and	O
mechanistic	O
studies	I:C0681814
on	O
the	O
action	O
of	O
GLP1	B:C0243192
-	I:C0243192
RA	I:C0243192
and	O
dipeptidyl	O
peptidase	I:C1827106
-	I:C1827106
4	I:C1827106
inhibitors	I:C1827106
on	O
the	O
cardiovascular	O
system	I:C0007226
,	O
both	O
deriving	O
from	O
clinical	O
and	O
pre-clinical	O
sources	O
.	O

This	O
review	O
is	O
aimed	O
at	O
collecting	O
and	O
summarizing	O
available	O
evidence	O
from	O
experimental	O
and	O
mechanistic	O
studies	I:C0681814
on	O
the	O
action	O
of	O
GLP1	O
-	I:C0243192
RA	I:C0243192
and	O
dipeptidyl	B:C1827106
peptidase	I:C1827106
-	I:C1827106
4	I:C1827106
inhibitors	I:C1827106
on	O
the	O
cardiovascular	O
system	I:C0007226
,	O
both	O
deriving	O
from	O
clinical	O
and	O
pre-clinical	O
sources	O
.	O

This	O
review	O
is	O
aimed	O
at	O
collecting	O
and	O
summarizing	O
available	O
evidence	O
from	O
experimental	O
and	O
mechanistic	O
studies	I:C0681814
on	O
the	O
action	O
of	O
GLP1	O
-	I:C0243192
RA	I:C0243192
and	O
dipeptidyl	O
peptidase	I:C1827106
-	I:C1827106
4	I:C1827106
inhibitors	I:C1827106
on	O
the	O
cardiovascular	B:C0007226
system	I:C0007226
,	O
both	O
deriving	O
from	O
clinical	O
and	O
pre-clinical	O
sources	O
.	O

The	O
results	O
of	O
cardiovascular	B:C0007226
outcome	O
trials	O
are	O
interpreted	O
on	O
the	O
basis	O
of	O
the	O
experimental	O
preclinical	O
data	I:C1516606
available	O
,	O
paying	O
particular	O
attention	O
to	O
the	O
heart	O
failure	I:C0018801
results	O
,	O
and	O
suggesting	O
some	O
novel	O
intriguing	O
hypotheses	O
to	O
explain	O
some	O
of	O
the	O
unexpected	O
findings	O
of	O
cardioprotection	O
of	O
incretin	O
-	O
based	O
drugs	O
.	O

The	O
results	O
of	O
cardiovascular	O
outcome	O
trials	B:C0008976
are	O
interpreted	O
on	O
the	O
basis	O
of	O
the	O
experimental	O
preclinical	O
data	I:C1516606
available	O
,	O
paying	O
particular	O
attention	O
to	O
the	O
heart	O
failure	I:C0018801
results	O
,	O
and	O
suggesting	O
some	O
novel	O
intriguing	O
hypotheses	O
to	O
explain	O
some	O
of	O
the	O
unexpected	O
findings	O
of	O
cardioprotection	O
of	O
incretin	O
-	O
based	O
drugs	O
.	O

The	O
results	O
of	O
cardiovascular	O
outcome	O
trials	O
are	O
interpreted	O
on	O
the	O
basis	O
of	O
the	O
experimental	B:C0681814
preclinical	O
data	I:C1516606
available	O
,	O
paying	O
particular	O
attention	O
to	O
the	O
heart	O
failure	I:C0018801
results	O
,	O
and	O
suggesting	O
some	O
novel	O
intriguing	O
hypotheses	O
to	O
explain	O
some	O
of	O
the	O
unexpected	O
findings	O
of	O
cardioprotection	O
of	O
incretin	O
-	O
based	O
drugs	O
.	O

The	O
results	O
of	O
cardiovascular	O
outcome	O
trials	O
are	O
interpreted	O
on	O
the	O
basis	O
of	O
the	O
experimental	O
preclinical	B:C1516606
data	I:C1516606
available	O
,	O
paying	O
particular	O
attention	O
to	O
the	O
heart	O
failure	I:C0018801
results	O
,	O
and	O
suggesting	O
some	O
novel	O
intriguing	O
hypotheses	O
to	O
explain	O
some	O
of	O
the	O
unexpected	O
findings	O
of	O
cardioprotection	O
of	O
incretin	O
-	O
based	O
drugs	O
.	O

The	O
results	O
of	O
cardiovascular	O
outcome	O
trials	O
are	O
interpreted	O
on	O
the	O
basis	O
of	O
the	O
experimental	O
preclinical	O
data	I:C1516606
available	O
,	O
paying	O
particular	O
attention	O
to	O
the	O
heart	B:C0018801
failure	I:C0018801
results	O
,	O
and	O
suggesting	O
some	O
novel	O
intriguing	O
hypotheses	O
to	O
explain	O
some	O
of	O
the	O
unexpected	O
findings	O
of	O
cardioprotection	O
of	O
incretin	O
-	O
based	O
drugs	O
.	O

The	O
results	O
of	O
cardiovascular	O
outcome	O
trials	O
are	O
interpreted	O
on	O
the	O
basis	O
of	O
the	O
experimental	O
preclinical	O
data	I:C1516606
available	O
,	O
paying	O
particular	O
attention	O
to	O
the	O
heart	O
failure	I:C0018801
results	O
,	O
and	O
suggesting	O
some	O
novel	O
intriguing	O
hypotheses	O
to	O
explain	O
some	O
of	O
the	O
unexpected	O
findings	O
of	O
cardioprotection	O
of	O
incretin	B:C1562292
-	O
based	O
drugs	O
.	O

The	O
results	O
of	O
cardiovascular	O
outcome	O
trials	O
are	O
interpreted	O
on	O
the	O
basis	O
of	O
the	O
experimental	O
preclinical	O
data	I:C1516606
available	O
,	O
paying	O
particular	O
attention	O
to	O
the	O
heart	O
failure	I:C0018801
results	O
,	O
and	O
suggesting	O
some	O
novel	O
intriguing	O
hypotheses	O
to	O
explain	O
some	O
of	O
the	O
unexpected	O
findings	O
of	O
cardioprotection	O
of	O
incretin	O
-	O
based	O
drugs	B:C1254351
.	O

In	O
particular	O
,	O
we	O
discuss	O
the	O
possible	O
contribution	O
to	O
the	O
incretin	B:C1562292
cardiovascular	O
effects	O
of	O
a	O
direct	O
cardiac	O
action	O
of	O
GLP	O
-	I:C0061355
1	I:C0061355
metabolites	O
through	O
GLP	O
-	I:C0378073
1	I:C0378073
receptor	I:C0378073
-	O
independent	O
pathways	O
,	O
and	O
of	O
DPP4	O
substrates	O
other	O
than	O
GLP	O
-	I:C0061355
1	I:C0061355
.	O

In	O
particular	O
,	O
we	O
discuss	O
the	O
possible	O
contribution	O
to	O
the	O
incretin	O
cardiovascular	B:C0007226
effects	O
of	O
a	O
direct	O
cardiac	O
action	O
of	O
GLP	O
-	I:C0061355
1	I:C0061355
metabolites	O
through	O
GLP	O
-	I:C0378073
1	I:C0378073
receptor	I:C0378073
-	O
independent	O
pathways	O
,	O
and	O
of	O
DPP4	O
substrates	O
other	O
than	O
GLP	O
-	I:C0061355
1	I:C0061355
.	O

In	O
particular	O
,	O
we	O
discuss	O
the	O
possible	O
contribution	O
to	O
the	O
incretin	O
cardiovascular	O
effects	O
of	O
a	O
direct	O
cardiac	B:C0018787
action	O
of	O
GLP	O
-	I:C0061355
1	I:C0061355
metabolites	O
through	O
GLP	O
-	I:C0378073
1	I:C0378073
receptor	I:C0378073
-	O
independent	O
pathways	O
,	O
and	O
of	O
DPP4	O
substrates	O
other	O
than	O
GLP	O
-	I:C0061355
1	I:C0061355
.	O

In	O
particular	O
,	O
we	O
discuss	O
the	O
possible	O
contribution	O
to	O
the	O
incretin	O
cardiovascular	O
effects	O
of	O
a	O
direct	O
cardiac	O
action	O
of	O
GLP	B:C0061355
-	I:C0061355
1	I:C0061355
metabolites	O
through	O
GLP	O
-	I:C0378073
1	I:C0378073
receptor	I:C0378073
-	O
independent	O
pathways	O
,	O
and	O
of	O
DPP4	O
substrates	O
other	O
than	O
GLP	O
-	I:C0061355
1	I:C0061355
.	O

In	O
particular	O
,	O
we	O
discuss	O
the	O
possible	O
contribution	O
to	O
the	O
incretin	O
cardiovascular	O
effects	O
of	O
a	O
direct	O
cardiac	O
action	O
of	O
GLP	O
-	I:C0061355
1	I:C0061355
metabolites	B:C0870883
through	O
GLP	O
-	I:C0378073
1	I:C0378073
receptor	I:C0378073
-	O
independent	O
pathways	O
,	O
and	O
of	O
DPP4	O
substrates	O
other	O
than	O
GLP	O
-	I:C0061355
1	I:C0061355
.	O

In	O
particular	O
,	O
we	O
discuss	O
the	O
possible	O
contribution	O
to	O
the	O
incretin	O
cardiovascular	O
effects	O
of	O
a	O
direct	O
cardiac	O
action	O
of	O
GLP	O
-	I:C0061355
1	I:C0061355
metabolites	O
through	O
GLP	B:C0378073
-	I:C0378073
1	I:C0378073
receptor	I:C0378073
-	O
independent	O
pathways	O
,	O
and	O
of	O
DPP4	O
substrates	O
other	O
than	O
GLP	O
-	I:C0061355
1	I:C0061355
.	O

In	O
particular	O
,	O
we	O
discuss	O
the	O
possible	O
contribution	O
to	O
the	O
incretin	O
cardiovascular	O
effects	O
of	O
a	O
direct	O
cardiac	O
action	O
of	O
GLP	O
-	I:C0061355
1	I:C0061355
metabolites	O
through	O
GLP	O
-	I:C0378073
1	I:C0378073
receptor	I:C0378073
-	O
independent	O
pathways	B:C1704259
,	O
and	O
of	O
DPP4	O
substrates	O
other	O
than	O
GLP	O
-	I:C0061355
1	I:C0061355
.	O

In	O
particular	O
,	O
we	O
discuss	O
the	O
possible	O
contribution	O
to	O
the	O
incretin	O
cardiovascular	O
effects	O
of	O
a	O
direct	O
cardiac	O
action	O
of	O
GLP	O
-	I:C0061355
1	I:C0061355
metabolites	O
through	O
GLP	O
-	I:C0378073
1	I:C0378073
receptor	I:C0378073
-	O
independent	O
pathways	O
,	O
and	O
of	O
DPP4	B:C0081937
substrates	O
other	O
than	O
GLP	O
-	I:C0061355
1	I:C0061355
.	O

In	O
particular	O
,	O
we	O
discuss	O
the	O
possible	O
contribution	O
to	O
the	O
incretin	O
cardiovascular	O
effects	O
of	O
a	O
direct	O
cardiac	O
action	O
of	O
GLP	O
-	I:C0061355
1	I:C0061355
metabolites	O
through	O
GLP	O
-	I:C0378073
1	I:C0378073
receptor	I:C0378073
-	O
independent	O
pathways	O
,	O
and	O
of	O
DPP4	O
substrates	O
other	O
than	O
GLP	B:C0061355
-	I:C0061355
1	I:C0061355
.	O

